George D. Demetri

63.6k total citations · 22 hit papers
346 papers, 38.0k citations indexed

About

George D. Demetri is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Oncology. According to data from OpenAlex, George D. Demetri has authored 346 papers receiving a total of 38.0k indexed citations (citations by other indexed papers that have themselves been cited), including 241 papers in Pulmonary and Respiratory Medicine, 144 papers in Gastroenterology and 115 papers in Oncology. Recurrent topics in George D. Demetri's work include Sarcoma Diagnosis and Treatment (154 papers), Gastrointestinal Tumor Research and Treatment (144 papers) and Gastric Cancer Management and Outcomes (65 papers). George D. Demetri is often cited by papers focused on Sarcoma Diagnosis and Treatment (154 papers), Gastrointestinal Tumor Research and Treatment (144 papers) and Gastric Cancer Management and Outcomes (65 papers). George D. Demetri collaborates with scholars based in United States, France and Germany. George D. Demetri's co-authors include Christopher D.�M. Fletcher, Michael C. Heinrich, Samuel Singer, Jonathan A. Fletcher, Margaret von Mehren, Christopher L. Corless, Robert G. Maki, Heikki Joensuu, Charles D. Blanke and Suzanne George and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

George D. Demetri

341 papers receiving 36.9k citations

Hit Papers

Efficacy and safety of sunitinib in patients with advance... 1998 2026 2007 2016 2006 2003 2003 2001 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    2006 1.9k citations George D. Demetri, Christopher R. Garrett et al. profile →
  2. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
    2003 1.8k citations Michael C. Heinrich, Christopher L. Corless et al. Science profile →
  3. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
    2003 1.7k citations Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology profile →
  4. Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
    2001 1.5k citations George D. Demetri et al. profile →
  5. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    2009 966 citations Ronald P. DeMatteo, Karla V. Ballman et al. profile →
  6. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
    2003 921 citations George D. Demetri et al. Journal of Clinical Oncology profile →
  7. NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
    2010 866 citations George D. Demetri, Margaret von Mehren et al. profile →
  8. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    2007 814 citations Suzanne George, Annick D. Van den Abbeele et al. profile →
  9. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
    2001 789 citations Samuel Singer, Anette Duensing et al. PubMed profile →
  10. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
    2008 768 citations Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology profile →
  11. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
    2008 750 citations Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology profile →
  12. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
    2006 609 citations Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology profile →
  13. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
    1998 606 citations George D. Demetri et al. Journal of Clinical Oncology profile →
  14. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
    2015 576 citations George D. Demetri, Margaret von Mehren et al. Journal of Clinical Oncology profile →
  15. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
    2008 564 citations Michael C. Heinrich, Robert G. Maki et al. Journal of Clinical Oncology profile →
  16. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
    2001 550 citations Samuel Singer, Christopher D.�M. Fletcher et al. profile →
  17. Molecular basis for sunitinib efficacy and future clinical development
    2007 546 citations George D. Demetri et al. profile →
  18. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
    2016 539 citations Patrick Schöffski, Sant P. Chawla et al. profile →
  19. KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
    2000 538 citations George D. Demetri, Samuel Singer et al. profile →
  20. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
    2008 436 citations Michael C. Heinrich, Kouros Owzar et al. Journal of Clinical Oncology profile →
  21. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
    2009 397 citations George D. Demetri, Sant P. Chawla et al. Journal of Clinical Oncology profile →
  22. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
    2017 361 citations Suzanne George, George D. Demetri et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
George D. Demetri United States 93 23.7k 17.0k 11.1k 8.9k 6.6k 346 38.0k
Robert G. Maki United States 88 18.3k 0.8× 8.0k 0.5× 9.7k 0.9× 5.3k 0.6× 3.9k 0.6× 377 26.3k
Ian Judson United Kingdom 79 16.5k 0.7× 6.4k 0.4× 10.8k 1.0× 5.0k 0.6× 6.0k 0.9× 403 28.0k
M. van Glabbeke Belgium 65 18.4k 0.8× 5.3k 0.3× 15.5k 1.4× 9.7k 1.1× 4.5k 0.7× 198 36.0k
Paolo G. Casali Italy 83 19.2k 0.8× 7.0k 0.4× 8.3k 0.7× 5.8k 0.6× 2.1k 0.3× 431 25.2k
Robert S. Benjamin United States 89 14.0k 0.6× 3.3k 0.2× 11.8k 1.1× 4.2k 0.5× 3.9k 0.6× 490 25.6k
Patrick Schöffski Belgium 68 9.5k 0.4× 2.7k 0.2× 9.6k 0.9× 3.2k 0.4× 4.8k 0.7× 510 19.4k
Allan T. van Oosterom Belgium 32 10.1k 0.4× 3.3k 0.2× 9.3k 0.8× 4.3k 0.5× 4.5k 0.7× 89 21.9k
Jaffer A. Ajani United States 101 26.9k 1.1× 6.7k 0.4× 16.8k 1.5× 21.2k 2.4× 8.8k 1.3× 939 45.2k
Yung‐Jue Bang South Korea 87 17.1k 0.7× 4.5k 0.3× 20.9k 1.9× 7.6k 0.9× 10.8k 1.6× 610 37.1k
Charles D. Blanke United States 57 9.6k 0.4× 6.5k 0.4× 8.5k 0.8× 5.8k 0.7× 2.2k 0.3× 292 18.5k

Countries citing papers authored by George D. Demetri

Since Specialization
Citations

This map shows the geographic impact of George D. Demetri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George D. Demetri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George D. Demetri more than expected).

Fields of papers citing papers by George D. Demetri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George D. Demetri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George D. Demetri. The network helps show where George D. Demetri may publish in the future.

Co-authorship network of co-authors of George D. Demetri

This figure shows the co-authorship network connecting the top 25 collaborators of George D. Demetri. A scholar is included among the top collaborators of George D. Demetri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George D. Demetri. George D. Demetri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hemming, Matthew L., Patrick Bhola, Leona A. Doyle, et al.. (2022). Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clinical Cancer Research. 28(11). 2397–2408. 6 indexed citations
2.
Hemming, Matthew L., Shannon Coy, Jia‐Ren Lin, et al.. (2021). HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clinical Cancer Research. 27(6). 1706–1719. 17 indexed citations
3.
Hemming, Matthew L., Changyu Fan, Chandrajit P. Raut, et al.. (2020). Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Molecular Cancer Research. 18(9). 1302–1314. 22 indexed citations
4.
Hemming, Matthew L., Matthew A. Lawlor, Rhamy Zeid, et al.. (2018). Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences. 115(25). E5746–E5755. 26 indexed citations
5.
Demetri, George D., Patrick Schöffski, Giovanni Grignani, et al.. (2017). Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. Journal of Clinical Oncology. 35(30). 3433–3439. 129 indexed citations
6.
Demetri, George D., Margaret von Mehren, Robin L. Jones, et al.. (2015). Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 34(8). 786–793. 576 indexed citations breakdown →
7.
Corless, Christopher L., Karla V. Ballman, Cristina R. Antonescu, et al.. (2014). Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 32(15). 1563–1570. 210 indexed citations
8.
Sicińska, Ewa, Jeffrey T. Czaplinski, Stephen P. Remillard, et al.. (2014). Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo. Molecular Cancer Therapeutics. 13(9). 2184–2193. 98 indexed citations
9.
Zhang, Yixiang, Jolieke G. van Oosterwijk, Ewa Sicińska, et al.. (2013). Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy. Clinical Cancer Research. 19(14). 3796–3807. 75 indexed citations
10.
Wagner, Andrew J., Rashmi Chugh, Lee S. Rosen, et al.. (2013). A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas. Clinical Cancer Research. 19(21). 6020–6029. 67 indexed citations
11.
Demetri, George D., Patrick Schöffski, Manisha H. Shah, et al.. (2012). Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research. 18(11). 3170–3179. 102 indexed citations
12.
Sasaki, Takaaki, Katsuhiro Okuda, Wei Zheng, et al.. (2010). The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research. 70(24). 10038–10043. 254 indexed citations
13.
DePrimo, Samuel E., Xin Huang, Martin E. Blackstein, et al.. (2009). Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure. Clinical Cancer Research. 15(18). 5869–5877. 38 indexed citations
14.
Demetri, George D., Iain R. Macpherson, Ding Wang, et al.. (2009). Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(19). 6232–6240. 126 indexed citations
15.
George, Suzanne, Priscilla Merriam, Robert G. Maki, et al.. (2009). Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. Journal of Clinical Oncology. 27(19). 3154–3160. 249 indexed citations
16.
Haining, W. Nicholas, Jeffrey K. Davies, Holger Kanzler, et al.. (2008). CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans. Clinical Cancer Research. 14(17). 5626–5634. 61 indexed citations
17.
Heinrich, Michael C., Robert G. Maki, Christopher L. Corless, et al.. (2008). Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 26(33). 5352–5359. 564 indexed citations breakdown →
18.
García‐Carbonero, Rocio, Judith Manola, Michael V. Seiden, et al.. (2004). Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. Journal of Clinical Oncology. 22(8). 1480–1490. 250 indexed citations
19.
Heinrich, Michael C., Christopher L. Corless, Anette Duensing, et al.. (2003). PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science. 299(5607). 708–710. 1767 indexed citations breakdown →
20.
Toppmeyer, Deborah, Andrew D. Seidman, Michaël Pollak, et al.. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.. PubMed. 8(3). 670–8. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert G. Maki Breakdown of academic impact, for papers by Ian Judson Breakdown of academic impact, for papers by M. van Glabbeke Breakdown of academic impact, for papers by Paolo G. Casali Breakdown of academic impact, for papers by Robert S. Benjamin Breakdown of academic impact, for papers by Patrick Schöffski Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Jaffer A. Ajani Breakdown of academic impact, for papers by Yung‐Jue Bang Breakdown of academic impact, for papers by Charles D. Blanke
Rankless by CCL
2026